Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_assertion type Assertion NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_head.
- NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_assertion description "[Similarly, there were no increased risks associated with the XRCC2 GA/AA genotype (OR, 0.98; 95% CI, 0.76-1.26 for breast cancer and OR, 0.93; 95% CI, 0.69-1.25 for ovarian cancer) or the XRCC3 CT/TT genotype (OR, 0.92; 95% CI, 0.77-1.10 for breast cancer and OR, 0.87; 95% CI, 0.71-1.08 for ovarian cancer).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_provenance.
- NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_assertion evidence source_evidence_literature NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_provenance.
- NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_assertion SIO_000772 15734952 NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_provenance.
- NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_assertion wasDerivedFrom befree-2016 NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_provenance.
- NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_assertion wasGeneratedBy ECO_0000203 NP482659.RA2mzjHyQ50P6tJX5Jg49fp1YdAA8ugkVeuX0k2D7D_dg130_provenance.